Comparative Pharmacology
Head-to-head clinical analysis: BALNEOL HC versus CORTALONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BALNEOL HC versus CORTALONE.
BALNEOL-HC vs CORTALONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. Binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress cytokine production.
Cortisone is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to suppress inflammation and immune response, and regulate metabolism.
Apply a thin layer to affected skin areas twice daily. For adult use, 1% hydrocortisone (as BALNEOL-HC) topical application.
10-40 mg orally once daily in the morning; for acute exacerbations, up to 60 mg/day divided into 2-4 doses.
None Documented
None Documented
Hydrocortisone: terminal half-life ~1.5–2.5 hours. With BALNEOL-HC (emollient + hydrocortisone 0.5%), systemic absorption after topical use is minimal (~2–5%), but prolonged application to damaged skin may increase systemic exposure, slightly prolonging half-life.
Terminal elimination half-life is 3-5 hours in patients with normal renal function; prolonged to 12-24 hours in severe renal impairment (CrCl <30 mL/min).
Primarily renal excretion of metabolites; <10% unchanged. Biliary/fecal elimination is negligible. In children undergoing whole-body application, percutaneous absorption can lead to systemic excretion of hydrocortisone metabolites.
Primarily renal (60-70% as unchanged drug), with 10-20% biliary/fecal.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid